InsidersTradesSigma
Follow the PTC Therapeutics, INC. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, PTC Therapeutics, INC. has logged 379 reports. Market capitalisation: €6.1bn. The latest transaction was filed on 28 August 2026 (Cession). Among the most active insiders: Almstead Neil Gregory. The full history is accessible without an account.
379
Insider Decl.
n/a
Thresholds
€184,586
1 ops.
Buy Volume
€28m
197 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PTC Therapeutics, INC. Buy (bullish), based on 14 analysts. Average price target: US$99.29.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,343 of 29,062 companies
75.8
score / 100
Value76
Quality76
FCF yld7.1%
Earn yld12%
EV/EBITDA9.6x
ROE·
Gross mgn97%
Net mgn39%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations379 total
6,874 shares@ US$72.74Common StockSEC:0001288952-26-000006:0
5,626 shares@ US$73.18Common StockSEC:0001288952-26-000006:1
11,890 shares@ US$71.55Common StockSEC:0001288952-26-000006:2
610 shares@ US$72.22Common StockSEC:0001288952-26-000006:3
50,000 shares@ US$73.000.060% mcap100.0% of flowCommonSEC144:0001628280-26-058901
5,335 shares@ US$72.860.0067% mcap14.8% of flowCommon StockSEC:0001288952-26-000004:0
7,165 shares@ US$73.670.0091% mcap20.1% of flowCommon StockSEC:0001288952-26-000004:1
9,419 shares@ US$70.780.011% mcap25.2% of flowCommon StockSEC:0001288952-26-000004:2
2,390 shares@ US$71.880.0029% mcap6.5% of flowCommon StockSEC:0001288952-26-000004:3
691 shares@ US$72.920.0009% mcap1.9% of flowCommon StockSEC:0001288952-26-000004:4
50,000 shares@ US$73.000.061% mcap100.0% of flowCommonSEC144:0001628280-26-058006
2,813 shares@ US$25.690.0012% mcap0.8% of flowCommon StockSEC:0001578852-26-000022:0
1,844 shares@ US$72.390.0022% mcap1.4% of flowCommon StockSEC:0001578852-26-000022:1
969 shares@ US$72.900.0012% mcap0.7% of flowCommon StockSEC:0001578852-26-000022:2
2,813 shares@ US$71.700.0033% mcap2.2% of flowCommonSEC144:0001959173-26-006063
10,292 shares@ US$68.570.012% mcap14.5% of flowCommon StockSEC:0001808968-26-000017:0
10,292 shares@ US$68.57310.012% mcap17.0% of flowCommonSEC144:0001959173-26-005607
4,000 shares0Common StockSEC:0002142653-26-000004:0
2,000 shares0Common StockSEC:0002142653-26-000004:1
3,494 shares@ US$80.350.0044% mcap20.1% of flowCommon StockSEC:0001984065-26-000008:0
3,494 shares@ US$80.34710.0044% mcap25.1% of flowCommonSEC144:0001959173-26-005220
2,464 shares@ US$46.540.0016% mcap0.5% of flowCommon StockSEC:0001578850-26-000023:0
2,464 shares@ US$90.250.0031% mcap0.9% of flowCommon StockSEC:0001578850-26-000023:1
10,000 shares@ US$42.950.0061% mcap12.2% of flowCommon StockSEC:0001866044-26-000005:0
10,000 shares@ US$90.000.013% mcap25.5% of flowCommon StockSEC:0001866044-26-000005:1
25 of 379 declarations
关于 PTC Therapeutics, INC.
PTC Therapeutics, Inc. (NASDAQ: PTCT) 是一家在美国上市的生物制药公司，总部位于美国新泽西州沃伦。对于国际投资者而言，PTC 最好被理解为一家专注于神经病学和代谢疾病的商业和研发特许经营权的罕见病专家。该公司成立于1990年代后期；美国证券交易委员会 (SEC) 记录显示其更名日期为1998年，这与其在罕见病药物开发方面的悠久运营历史相符。随着时间的推移，PTC 围绕高度未满足需求的适应症建立了一个产品组合，在这些适应症中，临床差异化和监管执行可能比广泛的初级保健规模更为重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) PTC 当前的投资案例由已上市产品和多元化管线共同驱动。其商业产品组合历来包括 Emflaza (deflazacort) 和 Translarna (ataluren)，两者在罕见病领域都非常重要，尽管这些特许经营权面临来自 Emflaza 的仿制药竞争和 Translarna 在欧洲的不利监管发展等逆风。最近，该公司通过用于苯丙酮尿症 (PKU) 的 Sephience (sepiapterin) 扩大了其增长平台。Sephience 于2025年在美国、欧洲经济区和日本获得了关键批准，随后于2026年2月在巴西获得批准。PTC 还在某些地区销售 Upstaza/Kebilidi。([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) 从竞争角度来看，PTC 在罕见病生物制药同行中占据了一个利基市场：它既不是大型多元化制药公司，也不是纯粹的早期研究公司。相反，它将商业执行与交易和特许权使用费货币化相结合。最近的一个重大事件是2025年12月将其剩余的 Evrysdi 特许权使用费流出售给 Royalty Pharma，同时保留与罗氏销售业绩相关的某些里程碑权利。另一个关键里程碑是与诺华公司就亨廷顿病药物 votoplam 达成的合作，这在2025年带来了大量的合作和许可收入，并为管线增加了战略选择性。([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm)) 从地理上看，PTC 在北美、欧洲和亚洲部分地区拥有全球业务，管理层表示 Sephience 有望在2026年底前扩展到20至30个国家。该公司的主要行政办公室位于新泽西州沃伦，其公开文件和公司通讯证实其在纳斯达克市场上市。对于投资者而言，PTC 提供了罕见病商业化、监管催化剂和上市执行的敞口，但也伴随着与报销、竞争和试验结果相关的典型生物技术风险。最近的财务更新显示 Sephience 的产品收入势头强劲，尽管传统产品仍面临压力。([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm))
